Pacira BioSciences reports financial results for first-quarter 2022
Click Here to Manage Email Alerts
Pacira BioSciences Inc. reported increased total revenue and net product sales in its first-quarter 2022 financial results, according to a press release.
The company reported a net income of $6.8 million and a total revenue of $158 million, an increase of 33% from the prior year period. Net product sales were $129.2 million for Exparel, $23.6 million for Zilretta and $3 million for Iovera, according to the release.
“We were delighted to end the first quarter of 2022 with record-high Exparel sales for the month of March, which underscores the significant progress we continue to make despite operational headwinds in the elective surgery market due to COVID and labor-related disruptions,” Dave Stack, chair and CEO of Pacira BioSciences, said in the release. “The successful integration of the Flexion acquisition was evidenced by strong Zilretta sales in the first quarter, which we expect to be an important near- and long-term contributor to earnings,” Stack added.
Pacira also highlighted the appointment of Daryl Gaugler as chief operating officer, which was effective May 4, 2022, according to the release.
Read more about
Click Here to Manage Email Alerts